EXEL News and Press, Exelixis Inc. From 05/19/22

Gainers: NeuroMetrix (NURO) +34%. Millicom International (TIGO) +32%. Grab Holdings (GRAB) +30%. SIGA Technologies (SIGA) +26%. Celyad Oncology (CYAD) +19%. Clene (CLNN) +19%. Applied Blockchain (APLD) +19%. Immunome (IMNM) +18%. BIT Mining (BTCM) +18%. Losers: Companhia Energetica de Minas G...

Exelixis (NASDAQ:EXEL) plunged 14% during day four of the  Cabometyx patent trial. Developing story ... For further details see: Exelixis drops quickly on day four of Cabometyx patent trial

Over the years, Exelixis' esteemed management successfully ramped up cabozantinib sales beyond the blockbuster range. Through many ongoing aggressive cabozantinib advancements, you can expect this blockbuster to grow by several more folds in revenue in the next few years. Meanwhil...

The stock market continues to be under pressure due to geopolitical tensions and various economic problems. But even in these challenging times, some companies are performing well. For instance, cancer-focused biotech company Exelixis (NASDAQ: EXEL) has run circles around the broade...

The stock market is highly volatile now. Some excellent growth stocks got hammered amid the uncertainty. But history has shown that stock market declines create opportunities. Investors with a long investment horizon and the stomach to bear the risk might not regret investing in these three...

Image source: The Motley Fool. Exelixis (NASDAQ: EXEL) Q1 2022 Earnings Call May 10, 2022 , 5:00 p.m. ET Operator Continue reading For further details see: Exelixis (EXEL) Q1 2022 Earnings Call Transcript

Exelixis, Inc. (EXEL) Q1 2022 Earnings Conference Call May 10, 2022, 05:00 PM ET Company Participants Susan Hubbard - EVP of Public Affairs and IR Mike Morrissey - President and CEO Chris Senner - CFO P.J. Haley - EVP of Commercial Vicki Goodman - Chief Medical Officer Peter Lamb - Chief Scie...

Exelixis saw its Q1 net income increase nearly 42 times higher year over year -- $68.6M compared to $1.6M -- helped in large part by a strong boost in sales from its cancer therapy Cabometyx (cabotinib). Revenue in the quarter of ~356M ($0.21 per share, basic and diluted) was a ~32% increase ...

Exelixis press release (NASDAQ:EXEL): Q1 Non-GAAP EPS of $0.26 beats by $0.03. Revenue of $355.98M (+31.7% Y/Y) misses by $7.24M. Re-affirms FY22 guidance. For further details see: Exelixis Non-GAAP EPS of $0.26 beats by $0.03, revenue of $355.98M misses by $7.24M

- Total Revenues of $356.0 million, Cabozantinib Franchise Revenues of $310.3 million - - GAAP Diluted EPS of $0.21, Non-GAAP Diluted EPS of $0.26 - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (Nasdaq: EXEL) today ...